Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 63

1.

Progress and perspectives in plant sterol and plant stanol research.

Jones PJH, Shamloo M, MacKay DS, Rideout TC, Myrie SB, Plat J, Roullet JB, Baer DJ, Calkins KL, Davis HR, Barton Duell P, Ginsberg H, Gylling H, Jenkins D, Lütjohann D, Moghadasian M, Moreau RA, Mymin D, Ostlund RE Jr, Ras RT, Ochoa Reparaz J, Trautwein EA, Turley S, Vanmierlo T, Weingärtner O.

Nutr Rev. 2018 Aug 7. doi: 10.1093/nutrit/nuy032. [Epub ahead of print]

PMID:
30101294
2.

Inhibition of Intestinal Cellular Glucose Uptake by Phenolics Extracted from Whole Wheat Grown at Different Locations.

Shamloo M, Jones PJH, Eck PK.

J Nutr Metab. 2018 Mar 18;2018:5421714. doi: 10.1155/2018/5421714. eCollection 2018.

3.

Activity-dependent modulation of hippocampal synaptic plasticity via PirB and endocannabinoids.

Djurisic M, Brott BK, Saw NL, Shamloo M, Shatz CJ.

Mol Psychiatry. 2018 Apr 18. doi: 10.1038/s41380-018-0034-4. [Epub ahead of print]

PMID:
29670176
4.

Drp1/Fis1 interaction mediates mitochondrial dysfunction, bioenergetic failure and cognitive decline in Alzheimer's disease.

Joshi AU, Saw NL, Shamloo M, Mochly-Rosen D.

Oncotarget. 2017 Dec 22;9(5):6128-6143. doi: 10.18632/oncotarget.23640. eCollection 2018 Jan 19.

5.

Inhibition of Drp1/Fis1 interaction slows progression of amyotrophic lateral sclerosis.

Joshi AU, Saw NL, Vogel H, Cunnigham AD, Shamloo M, Mochly-Rosen D.

EMBO Mol Med. 2018 Mar;10(3). pii: e8166. doi: 10.15252/emmm.201708166.

6.

An 8-week, open-label, dose-finding study of nimodipine for the treatment of progranulin insufficiency from GRN gene mutations.

Sha SJ, Miller ZA, Min SW, Zhou Y, Brown J, Mitic LL, Karydas A, Koestler M, Tsai R, Corbetta-Rastelli C, Lin S, Hare E, Fields S, Fleischmann KE, Powers R, Fitch R, Martens LH, Shamloo M, Fagan AM, Farese RV Jr, Pearlman R, Seeley W, Miller BL, Gan L, Boxer AL.

Alzheimers Dement (N Y). 2017 Sep 12;3(4):507-512. doi: 10.1016/j.trci.2017.08.002. eCollection 2017 Nov.

7.

Effects of genotype and temperature on accumulation of plant secondary metabolites in Canadian and Australian wheat grown under controlled environments.

Shamloo M, Babawale EA, Furtado A, Henry RJ, Eck PK, Jones PJH.

Sci Rep. 2017 Aug 22;7(1):9133. doi: 10.1038/s41598-017-09681-5.

8.

Discovery of novel brain permeable and G protein-biased beta-1 adrenergic receptor partial agonists for the treatment of neurocognitive disorders.

Yi B, Jahangir A, Evans AK, Briggs D, Ravina K, Ernest J, Farimani AB, Sun W, Rajadas J, Green M, Feinberg EN, Pande VS, Shamloo M.

PLoS One. 2017 Jul 26;12(7):e0180319. doi: 10.1371/journal.pone.0180319. eCollection 2017.

9.

Role of Endoplasmic Reticulum Stress in Learning and Memory Impairment and Alzheimer's Disease-Like Neuropathology in the PS19 and APPSwe Mouse Models of Tauopathy and Amyloidosis.

Briggs DI, Defensor E, Memar Ardestani P, Yi B, Halpain M, Seabrook G, Shamloo M.

eNeuro. 2017 Jul 14;4(4). pii: ENEURO.0025-17.2017. doi: 10.1523/ENEURO.0025-17.2017. eCollection 2017 Jul-Aug.

10.

A small molecule p75NTR ligand normalizes signalling and reduces Huntington's disease phenotypes in R6/2 and BACHD mice.

Simmons DA, Belichenko NP, Ford EC, Semaan S, Monbureau M, Aiyaswamy S, Holman CM, Condon C, Shamloo M, Massa SM, Longo FM.

Hum Mol Genet. 2016 Nov 15;25(22):4920-4938. doi: 10.1093/hmg/ddw316.

11.

Modulation of neuroinflammation and pathology in the 5XFAD mouse model of Alzheimer's disease using a biased and selective beta-1 adrenergic receptor partial agonist.

Ardestani PM, Evans AK, Yi B, Nguyen T, Coutellier L, Shamloo M.

Neuropharmacology. 2017 Apr;116:371-386. doi: 10.1016/j.neuropharm.2017.01.010. Epub 2017 Jan 13.

12.

Small molecule modulator of sigma 2 receptor is neuroprotective and reduces cognitive deficits and neuroinflammation in experimental models of Alzheimer's disease.

Yi B, Sahn JJ, Ardestani PM, Evans AK, Scott LL, Chan JZ, Iyer S, Crisp A, Zuniga G, Pierce JT, Martin SF, Shamloo M.

J Neurochem. 2017 Feb;140(4):561-575. doi: 10.1111/jnc.13917.

13.

Potential biomarkers to follow the progression and treatment response of Huntington's disease.

Disatnik MH, Joshi AU, Saw NL, Shamloo M, Leavitt BR, Qi X, Mochly-Rosen D.

J Exp Med. 2016 Nov 14;213(12):2655-2669. Epub 2016 Nov 7.

14.

Molecular and Neural Functions of Rai1, the Causal Gene for Smith-Magenis Syndrome.

Huang WH, Guenthner CJ, Xu J, Nguyen T, Schwarz LA, Wilkinson AW, Gozani O, Chang HY, Shamloo M, Luo L.

Neuron. 2016 Oct 19;92(2):392-406. doi: 10.1016/j.neuron.2016.09.019. Epub 2016 Sep 29.

15.

Novel, selective EPO receptor ligands lacking erythropoietic activity reduce infarct size in acute myocardial infarction in rats.

Kiss K, Csonka C, Pálóczi J, Pipis J, Görbe A, Kocsis GF, Murlasits Z, Sárközy M, Szűcs G, Holmes CP, Pan Y, Bhandari A, Csont T, Shamloo M, Woodburn KW, Ferdinandy P, Bencsik P.

Pharmacol Res. 2016 Nov;113(Pt A):62-70. doi: 10.1016/j.phrs.2016.08.013. Epub 2016 Aug 10.

PMID:
27521836
16.

Radicular anatomy of permanent mandibular second molars in an Iranian population: A preliminary study.

Akhlaghi NM, Abbas FM, Mohammadi M, Shamloo MR, Radmehr O, Kaviani R, Rakhshan V.

Dent Res J (Isfahan). 2016 Jul-Aug;13(4):362-6.

17.

Critical role of acetylation in tau-mediated neurodegeneration and cognitive deficits.

Min SW, Chen X, Tracy TE, Li Y, Zhou Y, Wang C, Shirakawa K, Minami SS, Defensor E, Mok SA, Sohn PD, Schilling B, Cong X, Ellerby L, Gibson BW, Johnson J, Krogan N, Shamloo M, Gestwicki J, Masliah E, Verdin E, Gan L.

Nat Med. 2015 Oct;21(10):1154-62. doi: 10.1038/nm.3951. Epub 2015 Sep 21.

18.

Alternation of secondary metabolites and quality attributes in Valencia Orange fruit ( Citrus sinensis ) as influenced by storage period and edible covers.

Shamloo MM, Sharifani M, Daraei Garmakhany A, Seifi E.

J Food Sci Technol. 2015 Apr;52(4):1936-47. doi: 10.1007/s13197-013-1207-4. Epub 2013 Nov 17.

19.

Alzheimer's therapeutics targeting amyloid beta 1-42 oligomers I: Abeta 42 oligomer binding to specific neuronal receptors is displaced by drug candidates that improve cognitive deficits.

Izzo NJ, Staniszewski A, To L, Fa M, Teich AF, Saeed F, Wostein H, Walko T 3rd, Vaswani A, Wardius M, Syed Z, Ravenscroft J, Mozzoni K, Silky C, Rehak C, Yurko R, Finn P, Look G, Rishton G, Safferstein H, Miller M, Johanson C, Stopa E, Windisch M, Hutter-Paier B, Shamloo M, Arancio O, LeVine H 3rd, Catalano SM.

PLoS One. 2014 Nov 12;9(11):e111898. doi: 10.1371/journal.pone.0111898. eCollection 2014.

20.

Small molecule p75NTR ligands reduce pathological phosphorylation and misfolding of tau, inflammatory changes, cholinergic degeneration, and cognitive deficits in AβPP(L/S) transgenic mice.

Nguyen TV, Shen L, Vander Griend L, Quach LN, Belichenko NP, Saw N, Yang T, Shamloo M, Wyss-Coray T, Massa SM, Longo FM.

J Alzheimers Dis. 2014;42(2):459-83. doi: 10.3233/JAD-140036.

21.

β1-adrenergic receptor activation enhances memory in Alzheimer's disease model.

Coutellier L, Ardestani PM, Shamloo M.

Ann Clin Transl Neurol. 2014 May 1;1(5):348-360.

22.

A death receptor 6-amyloid precursor protein pathway regulates synapse density in the mature CNS but does not contribute to Alzheimer's disease-related pathophysiology in murine models.

Kallop DY, Meilandt WJ, Gogineni A, Easley-Neal C, Wu T, Jubb AM, Yaylaoglu M, Shamloo M, Tessier-Lavigne M, Scearce-Levie K, Weimer RM.

J Neurosci. 2014 May 7;34(19):6425-37. doi: 10.1523/JNEUROSCI.4963-13.2014.

23.

Behavioral abnormalities and circuit defects in the basal ganglia of a mouse model of 16p11.2 deletion syndrome.

Portmann T, Yang M, Mao R, Panagiotakos G, Ellegood J, Dolen G, Bader PL, Grueter BA, Goold C, Fisher E, Clifford K, Rengarajan P, Kalikhman D, Loureiro D, Saw NL, Zhengqui Z, Miller MA, Lerch JP, Henkelman M, Shamloo M, Malenka RC, Crawley JN, Dolmetsch RE.

Cell Rep. 2014 May 22;7(4):1077-1092. doi: 10.1016/j.celrep.2014.03.036. Epub 2014 May 1.

24.

A small molecule TrkB ligand reduces motor impairment and neuropathology in R6/2 and BACHD mouse models of Huntington's disease.

Simmons DA, Belichenko NP, Yang T, Condon C, Monbureau M, Shamloo M, Jing D, Massa SM, Longo FM.

J Neurosci. 2013 Nov 27;33(48):18712-27. doi: 10.1523/JNEUROSCI.1310-13.2013. Erratum in: J Neurosci. 2014 Jan 29;34(5):2012.

25.

Inhibition of mitochondrial fragmentation diminishes Huntington's disease-associated neurodegeneration.

Guo X, Disatnik MH, Monbureau M, Shamloo M, Mochly-Rosen D, Qi X.

J Clin Invest. 2013 Dec;123(12):5371-88. doi: 10.1172/JCI70911. Epub 2013 Nov 15.

26.

A dramatic increase of C1q protein in the CNS during normal aging.

Stephan AH, Madison DV, Mateos JM, Fraser DA, Lovelett EA, Coutellier L, Kim L, Tsai HH, Huang EJ, Rowitch DH, Berns DS, Tenner AJ, Shamloo M, Barres BA.

J Neurosci. 2013 Aug 14;33(33):13460-74. doi: 10.1523/JNEUROSCI.1333-13.2013.

27.

A pharmacological screening approach for discovery of neuroprotective compounds in ischemic stroke.

Beraki S, Litrus L, Soriano L, Monbureau M, To LK, Braithwaite SP, Nikolich K, Urfer R, Oksenberg D, Shamloo M.

PLoS One. 2013 Jul 18;8(7):e69233. doi: 10.1371/journal.pone.0069233. Print 2013.

28.

GluN2B antagonism affects interneurons and leads to immediate and persistent changes in synaptic plasticity, oscillations, and behavior.

Hanson JE, Weber M, Meilandt WJ, Wu T, Luu T, Deng L, Shamloo M, Sheng M, Scearce-Levie K, Zhou Q.

Neuropsychopharmacology. 2013 Jun;38(7):1221-33. doi: 10.1038/npp.2013.19. Epub 2013 Jan 22.

29.

FoxO6 regulates memory consolidation and synaptic function.

Salih DA, Rashid AJ, Colas D, de la Torre-Ubieta L, Zhu RP, Morgan AA, Santo EE, Ucar D, Devarajan K, Cole CJ, Madison DV, Shamloo M, Butte AJ, Bonni A, Josselyn SA, Brunet A.

Genes Dev. 2012 Dec 15;26(24):2780-801. doi: 10.1101/gad.208926.112. Epub 2012 Dec 7.

30.

Stratification substantially reduces behavioral variability in the hypoxic-ischemic stroke model.

Pollak J, Doyle KP, Mamer L, Shamloo M, Buckwalter MS.

Brain Behav. 2012 Sep;2(5):698-706. doi: 10.1002/brb3.77. Epub 2012 Jul 16.

31.

Npas4: a neuronal transcription factor with a key role in social and cognitive functions relevant to developmental disorders.

Coutellier L, Beraki S, Ardestani PM, Saw NL, Shamloo M.

PLoS One. 2012;7(9):e46604. doi: 10.1371/journal.pone.0046604. Epub 2012 Sep 28.

32.

Deficits in cognition and synaptic plasticity in a mouse model of Down syndrome ameliorated by GABAB receptor antagonists.

Kleschevnikov AM, Belichenko PV, Faizi M, Jacobs LF, Htun K, Shamloo M, Mobley WC.

J Neurosci. 2012 Jul 4;32(27):9217-27. doi: 10.1523/JNEUROSCI.1673-12.2012.

33.

Thy1-hAPP(Lond/Swe+) mouse model of Alzheimer's disease displays broad behavioral deficits in sensorimotor, cognitive and social function.

Faizi M, Bader PL, Saw N, Nguyen TV, Beraki S, Wyss-Coray T, Longo FM, Shamloo M.

Brain Behav. 2012 Mar;2(2):142-54. doi: 10.1002/brb3.41.

34.

Identification of a central role for complement in osteoarthritis.

Wang Q, Rozelle AL, Lepus CM, Scanzello CR, Song JJ, Larsen DM, Crish JF, Bebek G, Ritter SY, Lindstrom TM, Hwang I, Wong HH, Punzi L, Encarnacion A, Shamloo M, Goodman SB, Wyss-Coray T, Goldring SR, Banda NK, Thurman JM, Gobezie R, Crow MK, Holers VM, Lee DM, Robinson WH.

Nat Med. 2011 Nov 6;17(12):1674-9. doi: 10.1038/nm.2543.

35.

Mouse model of Timothy syndrome recapitulates triad of autistic traits.

Bader PL, Faizi M, Kim LH, Owen SF, Tadross MR, Alfa RW, Bett GC, Tsien RW, Rasmusson RL, Shamloo M.

Proc Natl Acad Sci U S A. 2011 Sep 13;108(37):15432-7. doi: 10.1073/pnas.1112667108. Epub 2011 Aug 30.

36.

Autism-linked neuroligin-3 R451C mutation differentially alters hippocampal and cortical synaptic function.

Etherton M, Földy C, Sharma M, Tabuchi K, Liu X, Shamloo M, Malenka RC, Südhof TC.

Proc Natl Acad Sci U S A. 2011 Aug 16;108(33):13764-9. doi: 10.1073/pnas.1111093108. Epub 2011 Aug 1.

37.

Transplanted stem cell-secreted vascular endothelial growth factor effects poststroke recovery, inflammation, and vascular repair.

Horie N, Pereira MP, Niizuma K, Sun G, Keren-Gill H, Encarnacion A, Shamloo M, Hamilton SA, Jiang K, Huhn S, Palmer TD, Bliss TM, Steinberg GK.

Stem Cells. 2011 Feb;29(2):274-85. doi: 10.1002/stem.584.

38.

Comprehensive behavioral phenotyping of Ts65Dn mouse model of Down syndrome: activation of β1-adrenergic receptor by xamoterol as a potential cognitive enhancer.

Faizi M, Bader PL, Tun C, Encarnacion A, Kleschevnikov A, Belichenko P, Saw N, Priestley M, Tsien RW, Mobley WC, Shamloo M.

Neurobiol Dis. 2011 Aug;43(2):397-413. doi: 10.1016/j.nbd.2011.04.011. Epub 2011 Apr 17.

39.

Sex-specific cognitive deficits and regional brain volume loss in mice exposed to chronic, sublethal hypoxia.

Lan WC, Priestley M, Mayoral SR, Tian L, Shamloo M, Penn AA.

Pediatr Res. 2011 Jul;70(1):15-20. doi: 10.1203/PDR.0b013e31821b98a3.

40.

The sigma-1 receptor enhances brain plasticity and functional recovery after experimental stroke.

Ruscher K, Shamloo M, Rickhag M, Ladunga I, Soriano L, Gisselsson L, Toresson H, Ruslim-Litrus L, Oksenberg D, Urfer R, Johansson BB, Nikolich K, Wieloch T.

Brain. 2011 Mar;134(Pt 3):732-46. doi: 10.1093/brain/awq367. Epub 2011 Jan 28.

PMID:
21278085
41.

Long-term behavioral assessment of function in an experimental model for ischemic stroke.

Encarnacion A, Horie N, Keren-Gill H, Bliss TM, Steinberg GK, Shamloo M.

J Neurosci Methods. 2011 Mar 30;196(2):247-57. doi: 10.1016/j.jneumeth.2011.01.010. Epub 2011 Jan 21.

42.

Restoration of norepinephrine-modulated contextual memory in a mouse model of Down syndrome.

Salehi A, Faizi M, Colas D, Valletta J, Laguna J, Takimoto-Kimura R, Kleschevnikov A, Wagner SL, Aisen P, Shamloo M, Mobley WC.

Sci Transl Med. 2009 Nov 18;1(7):7ra17. doi: 10.1126/scitranslmed.3000258.

43.

The asparaginyl endopeptidase legumain after experimental stroke.

Ishizaki T, Erickson A, Kuric E, Shamloo M, Hara-Nishimura I, Inácio AR, Wieloch T, Ruscher K.

J Cereb Blood Flow Metab. 2010 Oct;30(10):1756-66. doi: 10.1038/jcbfm.2010.39. Epub 2010 Mar 17.

44.

Classical MHCI molecules regulate retinogeniculate refinement and limit ocular dominance plasticity.

Datwani A, McConnell MJ, Kanold PO, Micheva KD, Busse B, Shamloo M, Smith SJ, Shatz CJ.

Neuron. 2009 Nov 25;64(4):463-70. doi: 10.1016/j.neuron.2009.10.015.

45.

Expression and function of striatal enriched protein tyrosine phosphatase is profoundly altered in cerebral ischemia.

Braithwaite SP, Xu J, Leung J, Urfer R, Nikolich K, Oksenberg D, Lombroso PJ, Shamloo M.

Eur J Neurosci. 2008 May;27(9):2444-52. doi: 10.1111/j.1460-9568.2008.06209.x.

46.

Npas4, a novel helix-loop-helix PAS domain protein, is regulated in response to cerebral ischemia.

Shamloo M, Soriano L, von Schack D, Rickhag M, Chin DJ, Gonzalez-Zulueta M, Gido G, Urfer R, Wieloch T, Nikolich K.

Eur J Neurosci. 2006 Nov;24(10):2705-20.

PMID:
17156197
47.

Comprehensive regional and temporal gene expression profiling of the rat brain during the first 24 h after experimental stroke identifies dynamic ischemia-induced gene expression patterns, and reveals a biphasic activation of genes in surviving tissue.

Rickhag M, Wieloch T, Gidö G, Elmér E, Krogh M, Murray J, Lohr S, Bitter H, Chin DJ, von Schack D, Shamloo M, Nikolich K.

J Neurochem. 2006 Jan;96(1):14-29. Epub 2005 Nov 21.

48.

Death-associated protein kinase is activated by dephosphorylation in response to cerebral ischemia.

Shamloo M, Soriano L, Wieloch T, Nikolich K, Urfer R, Oksenberg D.

J Biol Chem. 2005 Dec 23;280(51):42290-9. Epub 2005 Oct 3.

49.
50.

Uncoupling protein-2 prevents neuronal death and diminishes brain dysfunction after stroke and brain trauma.

Mattiasson G, Shamloo M, Gido G, Mathi K, Tomasevic G, Yi S, Warden CH, Castilho RF, Melcher T, Gonzalez-Zulueta M, Nikolich K, Wieloch T.

Nat Med. 2003 Aug;9(8):1062-8. Epub 2003 Jul 13.

PMID:
12858170

Supplemental Content

Loading ...
Support Center